Navigation Links
ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist
Date:4/29/2010

WASHINGTON, April 29, 2010 The American Chemical Society Green Chemistry Institute (ACS GCI) Pharmaceutical Roundtable has awarded its 2010 research grant to Scottish chemist David Cole-Hamilton, Ph.D., for making great strides in expanding green chemistry and engineering practices in the global pharmaceutical industry. Cole-Hamilton will use the one-year $150,000-grant to further his study of the hydrogenation of amides to amines, resulting in improved benefits for the environment. He is the Irvine Professor of Chemistry, EaStCHEM, University of St. Andrews, Scotland.

Cole-Hamilton's research seeks to provide safer and environmentally friendly solutions to convert amides to amines, important in the development of many pharmaceutically active compounds. Conversion of the amide to the amine is usually conducted using a metallic hydride source such as sodium borohydride or lithium aluminum hydride.

The reactions are stoichiometric and large amounts of aluminum- or boron- containing side products are formed. Requiring separation from the desired amine product, these side products are usually disposed of in a landfill. The Roundtable identified greener amide reductions as one of the 12 key green chemistry research areas important for the pharmaceutical industry.

Cole-Hamilton's study will build upon exciting preliminary results, which proved it should be possible to use catalytic amide hydrogenation, which would only give water as a side product. If the catalyst is very active or can be recycled, there is no need for any significant waste from this reaction.

Since 2007 the grant program has awarded $800,000 toward research in the 12 key green chemistry research areas. All funding is made possible by a partnership between the ACS GCI and an alliance of major pharmaceutical companies Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Codexis, Dr. Reddy's, DSM Pharmaceutical Products, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer, and Roche.

Under the leadership of Cole-Hamilton, the St. Andrews group will collaborate with members of the Roundtable to improve the technology and allow it to be introduced widely and without restriction into the pharmaceutical industry. Major targets will be lowering the temperature and especially the pressure at which reactions are carried out, improving the selectivity toward the desired amines (currently 85-90 percent, with alcohols as the side products) and exploring scope and the functional group tolerance of the reaction.


'/>"/>

Contact: Julie Manley
j_manley@acs.org
815-325-4974
American Chemical Society
Source:Eurekalert  

Related biology news :

1. Study gives green light to plants’ role in global warming
2. Georgia Powers Green Energy Program Redesigned to Include More Solar Power
3. New York City Regional Extension Center Selects Greenway
4. New evidence that green tea may help fight glaucoma and other eye diseases
5. From bacteria to electricity: The future of green energy
6. Demystifying yield fluctuations for greenhouse tomatoes
7. Solid-state illuminator reduces nitrates in leafy green vegetables
8. Global study shows health joins green as business strategy
9. Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet
10. Spray application rate, equipment affect pest management in greenhouse ivy plants
11. More maize ethanol may boost greenhouse gas emissions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/23/2017)... La. (PRWEB) , ... March 23, 2017 , ... ... industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as ... customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has ...
(Date:3/22/2017)... , March 22, 2017  UBM and the ... announce their extended partnership and the third annual Massachusetts ... by the 21 st Annual MassMEDIC Conference ... place May 3-4, 2017. MassMEDIC ... Association (ADVAMED) President and CEO, Scott Whitaker ...
(Date:3/22/2017)... 22, 2017 The global chronic ... research report by Transparency Market Research (TMR). The top ... and AbbVie Inc., accounted for a share of only ... in this market are focusing aggressively on mergers, acquisitions, ... is likely to lead to market consolidation in the ...
Breaking Biology Technology: